← All trials
NCT05325346
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 7, 2022
- Primary completion
- May 15, 2022
- Completion date
- Oct 15, 2022
- First posted
- Apr 13, 2022
- Last posted
- Apr 13, 2022
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Veralox TherapeuticsLead sponsor
- CelerionCollaborator
- CelerionOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.